D. Ballinari

发表

Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.

A. Isacchi, E. Casale, C. Mercurio, 2010, Journal of medicinal chemistry.

In vitro cell growth pharmacodynamic studies: a new nonparametric approach to determining the relative importance of drug concentration and treatment time

Giuseppe De Nicolao, Paolo Magni, Italo Poggesi, 2003, Cancer Chemotherapy and Pharmacology.

Cancer Therapy : Preclinical NMS-E 973 , a Novel Synthetic Inhibitor of Hsp 90 with Activity against Multiple Models of Drug Resistance to Targeted Agents , Including Intracranial Metastases

A. Isacchi, E. Casale, E. Felder, 2013 .

NMS-E973, a Novel Synthetic Inhibitor of Hsp90 with Activity against Multiple Models of Drug Resistance to Targeted Agents, Including Intracranial Metastases

A. Isacchi, E. Casale, E. Felder, 2013, Clinical Cancer Research.

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer

Paola Storici, Cristina Alli, Maurizio Rocchetti, 2007, Molecular Cancer Therapeutics.

Biological profile of FCE 24517, a novel benzoyl mustard analogue of distamycin A.

D. Ballinari, E. Pesenti, G. Pezzoni, 1991, British Journal of Cancer.

A model-based approach to the in vitro evaluation of anticancer activity

G. De Nicolao, P. Magni, D. Ballinari, 2009, Cancer Chemotherapy and Pharmacology.

Catecholic flavonoids acting as telomerase inhibitors.

J. Trosset, R. D'Alessio, D. Ballinari, 2004, Journal of medicinal chemistry.

PHA-680632, a Novel Aurora Kinase Inhibitor with Potent Antitumoral Activity

D. Ballinari, V. Croci, P. Cappella, 2006, Clinical Cancer Research.

Novel anthracycline analogs.

D. Ballinari, G. Pezzoni, L. Capolongo, 1990, Cancer treatment reviews.

Modulation of multidrug resistance by verapamil or mdr1 anti‐sense oligodeoxynucleotide does not change the high susceptibility to lymphokine‐activated killers in mdr‐resistant human carcinoma (LoVo) line

T. Tsuruo, M. Colombo, R. Supino, 1990, International journal of cancer.

Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials.

G. Bonadonna, P. Casali, L. Gianni, 1990, Journal of the National Cancer Institute.

The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition

Andrea Lombardi Borgia, Antonella Isacchi, Roberta Bosotti, 2014, Molecular oncology.

102 Identification and preclinical characterization of NMS-P626, a potent, selective and orally bioavailable TrkA inhibitor with anti-tumor activity in a TrkA-dependent colorectal cancer

A. Isacchi, A. Borgia, D. Ballinari, 2010 .

Disulfide‐linked surface molecules of monoclonal antigen‐specific suppressor T cells: evidence for T cell receptor structures

P. Ricciardi-Castagnoli, M. Pierotti, L. Adorini, 1985, European journal of immunology.

Cell surface antigens of chemically induced fibrosarcomas: detection by a monoclonal antibody of a tumor-restricted Mr 12,000 protein gag antigen encoded by a dual-tropic murine leukemia virus.

M. Borrello, P. Radice, M. Pierotti, 1985, Cancer research.

BIOCHEMICAL ANALYSIS OF A PUBLIC H‐2 SPECIFICITY REVEALED BY AN ANOMALOUS REACTION OF AN ALLOANTISERUM WITH A CHEMICALLY INDUCED C57BL/10 FIBROSARCOMA

M. Pierotti, D. Ballinari, L. Grazioli, 1982, Journal of immunogenetics.

Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy

A. Isacchi, C. Mercurio, F. Colotta, 2010, Molecular Cancer Therapeutics.

Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: effect in mice bearing hepatic metastases

A. Rosato, D. Ballinari, C. Vízler, 1999, British Journal of Cancer.

Adoptive transfer of lymphokine-activated killer cells loaded with 4'-deoxy-4'-iododoxorubicin: therapeutic effect in mice bearing lung metastases.

A. Rosato, D. Ballinari, V. Bronte, 1994, Cancer research.

Establishment and genomic characterization of the new chordoma cell line Chor-IN-1

R. Bosotti, A. Isacchi, S. Di Bella, 2017, Scientific Reports.

4'-Iodo-4'-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid.

J. Palha, M. Saraiva, D. Ballinari, 2000, The American journal of pathology.

9-Fluorenone-2-Carboxylic Acid as a Scaffold for Tubulin Interacting Compounds.

S. Pieraccini, M. Sironi, D. Ballinari, 2013, ChemPlusChem.

Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding.

A. Isacchi, A. Montagnoli, R. D'Alessio, 2010, Journal of medicinal chemistry.

Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors.

D. Ballinari, V. Croci, D. Volpi, 2010, Journal of medicinal chemistry.

Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.

A. Isacchi, E. Casale, C. Mercurio, 2009, Journal of medicinal chemistry.

Characterization of papillomavirus polypeptides from bovine cutaneous fibropapillomas.

M. Pierotti, D. Ballinari, G. Della Porta, 1988, The Journal of general virology.

Cross‐reactions between tumor cells and allogeneic normal tissues. inhibition of a syngeneic lymphoma outgrowth in h‐2 and non‐h‐2 alloimmune balb/c mice

M. Colombo, M. Pierotti, D. Ballinari, 1982, International journal of cancer.

DBA/2‐like minor histocompatibility antigens on a BALB/c lymphoma. A balb/c anti‐DBA/2 serum which lyses the tumor and blocks balb/c anti‐tumor and anti‐DBA/2 effectors

M. Borrello, D. Ballinari, L. Grazioli, 1985, International journal of cancer.

Tumor-associated alien alloantigens of BALB/c tumors encoded by the MHC and by non-H-2 genes: a histogenetic study.

D. Ballinari, G. Parmiani, M. Sensi, 1980, Journal of immunology.

Design, Synthesis, and Biological Evaluation of Levoglucosenone‐Derived Ras Activation Inhibitors

E. Martegani, S. Colombo, D. Ballinari, 2009, ChemMedChem.

Ultrastructural cytoskeleton alterations and modification of actin expression in the NIH/3T3 cell line after transformation with Ha-ras-activated oncogene.

D. Ballinari, C. Traversari, I. Bongarzone, 1990, Cell motility and the cytoskeleton.

Expression of H-2 and viral antigens and resistance to the antitumor lysis of tunicamycin-treated MBL-2 lymphoma cells.

M. Colombo, M. Pierotti, D. Ballinari, 1983, Immunobiology.

Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.

A. Isacchi, E. Casale, J. Bischoff, 2010, Bioorganic & medicinal chemistry.

Molecular Cancer apeutics linical Development l Targeting of CDK and Tropomyosin Receptor Kinase ilies by the Oral Inhibitor PHA-848125 , an Agent Ther Broad-Spectrum Antitumor Efficacy

A. Isacchi, C. Mercurio, F. Colotta, 2010 .

A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.

A. Isacchi, A. Montagnoli, D. Ballinari, 2008, Nature chemical biology.

NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies

A. Isacchi, E. Felder, D. Ballinari, 2012, Molecular Cancer Therapeutics.

6‐Substituted Pyrrolo[3,4‐c]pyrazoles: An Improved Class of CDK2 Inhibitors

C. Mercurio, A. Vulpetti, D. Ballinari, 2007, ChemMedChem.

5-(2-amino-pyrimidin-4-yl)-1H-pyrrole and 2-(2-amino-pyrimidin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one derivatives as new classes of selective and orally available Polo-like kinase 1 inhibitors.

D. Ballinari, F. Fiorentini, M. Brasca, 2012, Bioorganic & medicinal chemistry letters.

Preclinical Development NMSP 937 , an Orally Available , Speci fi c Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies

A. Isacchi, E. Felder, D. Ballinari, 2012 .

Selective DNA interaction of the novel distamycin derivative FCE 24517.

M. Broggini, M. D’Incalci, E. Erba, 1991, Cancer research.

Monoclonal antibodies against NIH 3T3 cells transformed by human thyroid carcinoma DNA.

S. Ménard, P. Radice, S. Canevari, 1987, Hybridoma.

Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth.

A. Bardelli, P. Comoglio, S. Giordano, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Mcl-1 antagonism is a potential therapeutic strategy in a subset of solid cancers.

M. Modugno, D. Ballinari, W. Pastori, 2015, Experimental cell research.

Cell line identity finding by fingerprinting, an optimized resource for short tandem repeat profile authentication.

Angelo Nuzzo, Antonella Isacchi, Roberta Bosotti, 2013, Genetic testing and molecular biomarkers.

Antitumor Efficacy of Edotecarin as a Single Agent and in Combination with Chemotherapy Agents in a Xenograft Model

M. Ciomei, D. Ballinari, V. Croci, 2006, Clinical Cancer Research.

Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

R. Bosotti, A. Isacchi, E. Felder, 2016, Molecular Cancer Therapeutics.

Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death.

A. Isacchi, E. Casale, Daniel J. Anderson, 2013, Nature chemical biology.

LACK OF H‐2Ld LOCUS PRODUCTS ON A BALB/c FIBROSARCOMA EXPRESSING H‐2k‐LIKE ALIEN ANTIGENS

M. Pierotti, D. Ballinari, G. Parmiani, 1983, Journal of immunogenetics.

Genetic control of in vivo immunity to tumor‐specific transplantation antigens of chemically induced murine fibrosarcomas

D. Ballinari, G. Parmiani, 1979, International journal of cancer.

Establishment of l1210 leukemia cells resistant to the distamycin‐a derivative (FCE 24517): Characterization and cross‐resistance studies

G. Tagliabue, M. Broggini, E. Erba, 1993, International journal of cancer.

Expression of alien minor histocompatibility antigens distinct from tumor‐specific transplantation antigen on a murine fibrosarcoma

D. Ballinari, G. Parmiani, Giorgio Parmiani, 1980, International journal of cancer.

Dioxin and Ecological Risk Assessment

D. Ballinari, E. Pesenti, G. Pezzoni, 1993, Environmental Health Perspectives.

Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury

R. Bosotti, A. Isacchi, A. Montagnoli, 2017, Molecular Cancer Therapeutics.

Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.

A. Isacchi, G. Canevari, E. Felder, 2014, Bioorganic & medicinal chemistry.

C. Melchiorre, D. Ballinari, G. Sagratini, 2009, Journal of medicinal chemistry.

ORIGINAL H‐2d AND FOREIGN H ‐ 2k ‐ LIKE ANTIGENS ARE INDEPENDENT ENTITIES ON A CHEMICALLY INDUCED SARCOMA

D. Ballinari, G. Parmiani, A. Meschini, 1978, Journal of immunogenetics.

Early lymphocyte activation molecule defined by the monoclonal antibody MLR-3: biochemical and functional studies.

G. Cattoretti, D. Delia, D. Ballinari, 1988, Immunology.

Nemorubicin: A doxorubicin-like structure with a novel mechanism of action different from anthracyclines

M. Sabatino, M. Broggini, M. Ciomei, 2006 .

Reversal of multidrug resistance by new dihydropyridines with low calcium antagonist activity.

D. Ballinari, M. Ripamonti, L. Capolongo, 1994, Acta oncologica.

Abstract 4785: NMS-E668, a highly potent orally available RET inhibitor with selectivity towards VEGFR2 and demonstrated antitumor efficacy in multiple RET-driven cancer models

A. Isacchi, E. Felder, A. Borgia, 2018, Experimental and Molecular Therapeutics.